Israeli medical device maker Alpha Tau raises $26 million to fund trials

 

 

JERUSALEM (Reuters) - Israeli medical device maker Alpha Tau Medical said on Thursday it raised $26 million in a funding round from investors including Shavit Capital, Medison Ventures and OurCrowd to help finance global clinical trials.

 

Alpha Tau said it has successfully completed its first-in-human clinical trial of Alpha DaRT — a radiation cancer therapy — with squamous cell carcinoma patients from Italy and Israel.

 

It is now conducting trials in other sites, such as its first U.S. trial at Memorial Sloan Kettering Cancer Center in New York, a pancreatic cancer trial at CHUM in Montreal and trials at three academic institutions in Japan.

 

The company, it said, is also establishing new manufacturing facilities in Israel and elsewhere.

 

Reporting by Steven Scheer; Editing by Tova Cohen

Our Standards:The Thomson Reuters Trust Principles.

 

 

The original article can be found at: https://uk.reuters.com/article/uk-tech-fundraising-alpha-tau-idUKKBN23B1NX;

A copy of this article can also be found at: https://www.nytimes.com/reuters/2020/06/04/technology/04reuters-tech-fundraising-alpha-tau.html.

 


 

Share on Facebook
Share on Twitter
Please reload

Please reload

Featured Posts

How Israeli technology saved 78-year-old Leah from skin cancer

1/9
Please reload

Archive
Please reload

Categories
Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon
Alpha Tau

Looking for clinical trials?

  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon